Clinical Trials Logo

Varicella clinical trials

View clinical trials related to Varicella.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05839301 Active, not recruiting - Varicella Clinical Trials

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Start date: April 27, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

NCT ID: NCT05669625 Active, not recruiting - Varicella Clinical Trials

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Start date: December 26, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

NCT ID: NCT05470855 Active, not recruiting - Varicella Clinical Trials

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

Start date: July 6, 2022
Phase: Phase 4
Study type: Interventional

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.

NCT ID: NCT03330171 Active, not recruiting - Measles Clinical Trials

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine

MV/VV/Hep-AV
Start date: April 10, 2017
Phase: Phase 4
Study type: Interventional

This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and iii) a single dose of hepatitis-A vaccination at 18 months in HIV-exposed and HIV-unexposed South African children.